Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8233 in dyslipidemia (ETESIAN)
NCT04641299Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Primary completion
- Jul 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of AZD8233 in dyslipidemia (4 arms), sponsored by AstraZeneca. Primary endpoint: Change in Low-density Lipoprotein Cholesterol at 12 weeks. Started Oct 2020; status: completed.
02
Drugs
AZD8233
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT04641299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04641299.